Clinical Trials Directory

Trials / Conditions / CD19 Positive

CD19 Positive

12 registered clinical trials studyying CD19 Positive — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingSubcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (M
NCT07222579
West Virginia UniversityPhase 2
Active Not RecruitingModified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom
NCT04007029
Jonsson Comprehensive Cancer CenterPhase 1
WithdrawnCAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transp
NCT03579927
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingPembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leuke
NCT03512405
City of Hope Medical CenterPhase 1 / Phase 2
UnknownCRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
NCT04037566
Xijing HospitalPhase 1
WithdrawnModified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive,
NCT04029038
M.D. Anderson Cancer CenterPhase 1 / Phase 2
UnknownHuman CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
NCT03798509
Hrain Biotechnology Co., Ltd.Phase 1
UnknownHuman CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
NCT03720457
Hrain Biotechnology Co., Ltd.Phase 1
Active Not RecruitingStudy of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refrac
NCT03241940
Stanford UniversityPhase 1
Active Not RecruitingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refract
NCT03233854
Stanford UniversityPhase 1
UnknownCD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
NCT03275493
Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdPhase 1 / Phase 2
CompletedCD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
NCT02529813
M.D. Anderson Cancer CenterPhase 1